AJKD

The American Journal of Kidney Diseases is the official journal of @nkf | |

[AJKD @AJKDonline]

The July 2026 issue of AJKD is available now!

Check out the plain-language summaries on what inspired each study, the basic approach taken, what was learned, and why it matters:

https://t.co/H2XWy6KArJ

[Duke Kidney @DukeKidney]

New from #NephFaculty Dr Strasma and colleagues in AJKD

Environmental Threats to Kidney Health: A Clinician's Guide to Modern Exposures

https://t.co/enBZK1ea9D

[AJKD @AJKDonline]

Palliative Dialysis: Putting the Person First in Dialysis Care

https://t.co/ahkmlm7A0o (OPEN ACCESS)

[Wisit Cheungpasitporn MD FACP | FASN | FAST @wisit661]

📖 Read our article for free (available for a limited time):
https://t.co/3bWQSBv5Pc

We are pleased to share our latest publication in the American Journal of Kidney Diseases (AJKD): @AJKDonline @napatlee1

Deceased Donor Kidney Transplantation Versus Continued Dialysis Among Patients Aged 75 Years or Older: A Target Trial Emulation

As the population of older adults with kidney failure continues to grow, determining which patients benefit most from kidney transplantation is increasingly important. Using a target trial emulation framework, we compared deceased donor kidney transplantation with continued dialysis among patients aged 75 years or older to provide evidence that can better inform transplant evaluation and shared decision-making.

Citation

Leeaphorn N, Attieh RM, Oshel KM, Mai ML, Prendergast M, Wadei HM, Garcia Valencia OA, Cheungpasitporn W, Jarmi T.

American Journal of Kidney Diseases. 2026. Online ahead of print.

DOI: 10.1053/j.ajkd.2026.02.647
@MayoClinicNeph
#Nephrology #KidneyTransplant #Dialysis #AJKD #ClinicalResearch #TargetTrialEmulation #EvidenceBasedMedicine #MayoClinic

[AJKD @AJKDonline]

Temporal Trends in the Complexity of Nephrology Inpatients: A Population-Based Cohort Study

https://t.co/qcJTo8qksP (OPEN ACCESS)

@Mesangialman @NwiebeWiebe @BHemmelgarn1 @BradenMannsYYC @cellotonelli

[AJKD @AJKDonline]

Clinical and Social Risk Factors for 30-Day Readmissions in Children With Kidney Disease

@lelavillegas @Cervantes_Lily1 @zjmodi

https://t.co/UORKYi9xXG

[AJKD @AJKDonline]

#KDOQI US Commentary on the @goKDIGO 2024 Clinical Practice Guideline for the Management of Lupus Nephritis

https://t.co/KMZke76o3G (FREE)

@SaynaNorouzi @NKF_NephPros

[Sayna Norouzi, MD, FASN @SaynaNorouzi]

Our #KDOQI US Commentary on the #KDIGO Lupus Nephritis guidelines is officially out!! Such a pleasure working with a fantastic team on this.

I loved diving into a topic I'm genuinely passionate about; SO much is changing in #Lupus #Nephritis treatment. It's time we start looking at #LN differently.

#KDIGO #Guidelines #CART #Innovation #RareKidneyDisease @NKF_NephPros
@AJKDonline ⭐️🙌🏻

[Mary Cushman 🫀🧠🩸 @MaryCushmanMD]

So proud of our consortium research on impacts of COVID on health. #C4R
@UVMLarnerMed @UVMDeptMed

[AJKD @AJKDonline]

NEW Blog Commentary from AJKD Editorial Intern Kashvi Gupta on the #AJKDBlog:

Why Physical Function Matters More Than We Think in CKD

https://t.co/2zjtaO45z1 (FREE)

[AJKD @AJKDonline]

Review on therapies for proliferative and membranous lupus nephritis with a focus on strategies targeting underlying mechanisms of disease in LN:

“A Change Is Gonna Come” to Treatment of Lupus Nephritis

https://t.co/3aCXnJfnIj (FREE)

@TWhittier_RUSH @Rush_Nephrology

[AJKD @AJKDonline]

Associations of Pre-Pandemic CKD With Acute and Post-Acute COVID-19: The C4R Study

https://t.co/nAhsdEyGAZ (OPEN ACCESS)

@kramer_holly @MaryCushmanMD @alka_kanaya

[Nephrology News & Issues @Nephronline]

To address nephrology's growing complexity, Anukul Ghimire, MD, MSc, and Marcello Tonelli MD, SM, MSc said “sustainable methods of care” are needed, such as

⭐ Task-shifting
⭐ Modifying reimbursement models
⭐ Utilizing AI to manage cognitive load

More:
https://t.co/4nJ0RvKgLv

[AJKD @AJKDonline]

Seasonality, Hospitalization, and Initiation of Home Dialysis: A Retrospective Cohort Study

https://t.co/NR9gOc2w8F

@eugelin06 @USCSchaeffer @KeckKidneys

[AJKD @AJKDonline]

This Special Collection features the top cited Original Investigations published in 2023 and 2024 that contributed to AJKD’s 2025 Impact Factor of 9.4:

https://t.co/sFg66RZ8Tp (FREE)

[Duke Kidney @DukeKidney]

New from Dr Barisoni and colleagues in AJKD

Association of Histological Features of Cortical and Medullary Peritubular Capillaries With Progressive CKD

https://t.co/CRWmtdiLTX

[NKF Nephrology Professionals @NKF_NephPros]

Guidelines are one thing. Applying them in practice is another.

Hear how experts interpret KDIGO recommendations for IgAN and IgAV in real world care.

🎧 Listen now: https://t.co/RGuDW0NrDB (Episode 056)

#Nephrology #ClinicalPractice #KDOQI

[AJKD @AJKDonline]

Metabolic Acidosis and Progression of CKD: Current Guidelines and Considerations

https://t.co/seXwTODp8i

@theCKDdietitian @WesleyVisser @AndrewMorrisRD

[Vineeta Kumar @VineetaKumar8]

Honored to be part of this working group

[Mayo Clinic Nephrology @MayoClinicNeph]

Association of Histological Features of Cortical and Medullary Peritubular Capillaries With Progressive CKD

@AJKDonline @AndrewRuleMD

https://t.co/Muf01YErKw

[AJKD @AJKDonline]

@winkeldoc @Khairallah_P @MingyueHe3 @MontezRath @taraichang @BCMKidneyHealth Editorial by An S. De Vriese:

Anticoagulation Decisions in Patients With Kidney Failure Requiring Hemodialysis: Caught Between a Clot and a Hard Place

https://t.co/dhdrEhCzdB (FREE)

[AJKD @AJKDonline]

Effectiveness and Safety of Apixaban Initiation Following Newly-Diagnosed Atrial Fibrillation in Patients With Kidney Failure on Hemodialysis

https://t.co/Ha8ZMmL4TH

@winkeldoc @Khairallah_P @MingyueHe3 @MontezRath @taraichang @BCMKidneyHealth